Why Cyber Specialists Thrive During Economic Downturns
New INE Security Analysis Shows Targeted Cybersecurity Training Creates Career Stability in Uncertain Times
Cary, NC, May 30, 2025 (GLOBE NEWSWIRE) -- While tech giants have eliminated 300,000+ jobs over two years, cybersecurity professionals face a different reality. Organizations desperately need cybersecurity talent, yet many positions remain unfilled -- not from lack of demand, but because employers won't settle for candidates without specialized skills. This creates a unique opportunity: professionals who invest in targeted cybersecurity education and security certifications can build recession-proof careers while others struggle.INE Security, a leading provider of cybersecurity training and certifications, analyzed this market dynamic and found that specialization doesn't just improve job prospects, it multiplies career value exponentially."Specialization in cybersecurity creates a career insurance policy that generalists simply can't match," explains Dara Warn, CEO of INE Security. "While general IT professionals compete on price and availability, specialists compete on unique value. When you're one of the few professionals in your region who can architect zero-trust implementations or perform advanced mobile pentesting, you're not just employed – you're essential."The Math That Matters: Why Specialization PaysThe U.S. Bureau of Labor Statistics projects 33% growth for information security analysts through 2033, which is ten times faster than the average occupation. But despite 87% of companies reporting cybersecurity skill gaps (McKinsey & Company), many are willing to wait for the right candidates rather than hire generalists.This creates a mathematical advantage for specialists. When hundreds apply for general IT roles, specialized positions like mobile security pentester or cloud architect often struggle to find even five qualified candidates. That scarcity translates directly into negotiating power and compensation opportunities.The $4.88 Million QuestionWith the average cybersecurity breach spiking 10% over the last year to $4.88 million (IBM Ponemon Institute), organizations can't afford mediocre security. They need specialists who can prevent, detect, and respond to threats immediately. Since 68% of breaches involve human elements like social engineering, according to Verizon's 2024 Data Breach Investigations Report, employers seek professionals who understand both technical vulnerabilities and human behavior patterns.This urgency explains why 91% of hiring managers prefer certified candidates (Fortinet) and why specialized roles command premium rates:
: The global pentesting market will grow from $2.74 billion to $6.25 billion by 2032. Certified pentesters with hands-on experience often earn double general security salaries (Fortune Business Insights).
: With 38% of mobile apps containing high-risk vulnerabilities, mobile security specialists are in extreme demand but short supply (Positive Technologies).
: Specialists command emergency rates exceeding $750/hour because when breaches happen, organizations need immediate expertise, not someone learning on the job (Industry Research).
The Certification Advantage: Real NumbersProfessional certifications create measurable career advantages beyond just knowledge validation. Gallup research shows 81% of Americans with professional certifications are employed versus 68% without them. In cybersecurity, this advantage amplifies because security certifications prove competency in high-stakes scenarios.From foundational credentials like Sec+ to advanced pentester certifications, the progression path is clear. Career advancement opportunities expand dramatically with specialized certifications. This motivation helps combat feelings of career stagnation that contribute to burnout, an increasingly critical problem within the cybersecurity industry. But certifications alone aren't enough—employers increasingly demand proven practical experience.Beyond Paper: Why Hands-On Training Multiplies ValueThe business case is compelling: well-trained cybersecurity teams generate $70,000 in annual savings and 10% productivity increases (IBM). Organizations recognize this ROI, which explains why 67% prefer team members with certifications - they validate both knowledge and practical capability (Fortinet).Modern cybersecurity education leverages cyber ranges and virtual labs that simulate real attack scenarios. This allows professionals to practice incident response, penetration testing, and threat analysis without risking production systems. The result? Professionals who can demonstrate actual competency rather than just theoretical knowledge.Real-World Application: The eMAPT ExampleINE Security's enhanced Mobile Application Penetration Tester (eMAPT) certification exemplifies this integrated approach. Beyond advanced mobile security methodologies, the program includes extensive hands-on exercises in dedicated cyber ranges that replicate real mobile application infrastructures. Through June 24, 2025, learners can save $200 on the eMAPT certification and gain access to INE Security's updated Mobile Application Penetration Testing Learning Path.Learners practice iOS and Android security assessment against actual vulnerabilities in controlled environments. This combination of security certifications and practical lab experience addresses the core employer demand: verifiable expertise backed by demonstrated capability.The Ultimate Career Insurance PolicyThe cybersecurity profession rewards those who invest in continuous learning through specialized training. The combination of recognized security certifications, hands-on laboratory experience, and practical skill application creates professionals who thrive regardless of economic conditions.While traditional IT training paths may offer broader options, cybersecurity education provides something more valuable: career resilience in an increasingly uncertain world. As threats evolve and breach costs climb, organizations will continue prioritizing specialists who can deliver immediate value.About INE Security:INE Security is the premier provider of online networking and cybersecurity training and cybersecurity certifications. Harnessing a powerful hands-on lab platform, cutting-edge technology, a global video distribution network, and world-class instructors, INE Security is the top training choice for Fortune 500 companies worldwide for cybersecurity training in business and for IT professionals looking to advance their careers. INE Security's suite of learning paths offers an incomparable depth of expertise across cybersecurity and is committed to delivering advanced technical training while also lowering the barriers worldwide for those looking to enter and excel in an IT career.
CONTACT: Kathryn Brown INE kbrown@ine.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Following Successful Merger With Roanoke-Based Member One, Virginia Credit Union To Unify Brand, Operations in 2026
Member One Members Will Continue to Bank as They Have Until Transition to Virginia Credit Union Brand in Spring 2026 One Brand. One Vision. RICHMOND, Virginia, June 03, 2025 (GLOBE NEWSWIRE) -- Following a successful merger in August 2024, Virginia Credit Union and its Member One division are pleased to announce that the now-combined organization will operate in all markets as Virginia Credit Union, beginning in the spring of 2026. 'The Virginia Credit Union brand has almost a century of history behind it and boasts a proven track record as a member-focused organization, one that's driven by its mission and focused on delivering value for members through its products, services, and resources,' said Virginia Credit Union President/CEO Chris Shockley. 'We know this merger will continue to benefit our members, staff, and the communities we proudly serve, and we look forward to further building on our proud tradition of member and community service under the Virginia Credit Union name.' The brand decision follows an extensive brand research project and a careful evaluation of both brands' strengths and awareness in current markets. Several factors were considered in selecting Virginia Credit Union as the continuing brand. Virginia Credit Union has operated continuously for almost a century. Its recognition as a brand is unmatched in many of its core markets, and it enjoys a sterling reputation for its products and services, financial education resources, and community engagement work. By moving forward as a unified brand, Virginia Credit Union is better positioned to create a cohesive and consistent member experience that further cements its reputation as a trusted financial services provider and community leader. Owing to its long history of service to state employees, including staff at various state and local government agencies, as well as colleges and universities, the Virginia Credit Union brand enjoys strong awareness across the Commonwealth, even in areas outside its original core markets, including those communities served by Member One. As a member-owned, not-for-profit cooperative, and in light of the need to be good stewards of members' resources, the significant cost associated with the various competing brand options was also an important consideration. Also considered were the inefficiencies that would result if the organization continued to operate as two distinct brands. The credit union will work through 2025 and into 2026 in preparation for Operational Day One, the date legacy Member One operations will be fully integrated into Virginia Credit Union — operating under the same brand and with the same systems, products, and services. Operational Day One will likely occur in the spring of 2026, and the credit union is committed to ensuring a carefully considered and member-centric approach to the integration project. Legacy Member One members will continue to bank as they have for the foreseeable future, utilizing Member One's online and mobile banking platforms, lending services, call centers, and branch locations. Through timely communications, members will be informed of integration milestones and member service updates as the credit union moves through the integration process. 'The most appealing aspect of this merger was the fact that our two organizations shared a belief that what we do and what we offer has a meaningful and positive impact on members and our communities,' said Shockley. 'We put people first and believe the relationships we build with members and within our communities are helping members achieve greater financial success and building stronger, more resilient communities. Combining these two well-respected and trusted organizations under one unified brand will only bolster our ability to fulfill our mission.' Member One members can learn more about the planned rebrand to Virginia Credit Union here. About Virginia Credit Union & Member OneA financial cooperative serving almost 500,000 members, Virginia Credit Union and its Member One division offer a variety of affordable banking services, loans, mortgages, and free financial education resources, with a focus on helping people be more confident with their finances. Virginia Credit Union and its Member One division are equal housing opportunity lenders and are federally insured by the NCUA. Attachment One Brand. One Vision. CONTACT: Lewis Wood Virginia Credit Union 804-560-5664
Yahoo
an hour ago
- Yahoo
SUCCESS® Magazine's Business Of Sports Issue Hits Newsstands
Industry athletes accelerate in all facets of life SUCCESS® Magazine's Business Of Sports Issue Hits Newsstands DALLAS, June 03, 2025 (GLOBE NEWSWIRE) -- Today, SUCCESS® magazine revealed Tim and Demi-Leigh Tebow, former NFL Broncos quarterback and Miss Universe 2017, proponents of the Tim Tebow Foundation on the cover of its July/August 2025 issue. Dubbed the Business of Sports issue, the magazine's exclusive content is spotlighting athletes, coaches, sport agents, and executives who are extending their influence from sports arenas to leadership, entrepreneurship, and social impact. 'Charting excellence in athletic performance and beyond the field in integrative careers, the sports world is producing meaningful, mission-driven industry leaders,' says Kerrie Lee Brown, editor-in-chief and VP Publishing of SUCCESS® Enterprises. 'I had the opportunity to sit down with Tim and Demi-Leigh Tebow, two inspiring advocates of humanitarian change with their incredible foundation. We discussed their commitment to helping vulnerable children in need, disability awareness, and their determined steps to dismantling human trafficking. Their journey is one of compassion and an allegiance to sparking real transformation.' Tim Tebow, an influential force in the football world, transitioned from his athletic passion to philanthropic and entrepreneurial ventures. Demi-Leigh Tebow, former Miss Universe and Miss South Africa, is the author of A Crown That Lasts, Princess Paris Finds Her Purpose, and creator of self-defense initiatives for women through her platform. Together, the Tebows are a powerful force, united in their mission to inspire hope, faith, love, and a lasting impact around the world. The premise behind SUCCESS® magazine's Business of Sports issue is to showcase dynamic sports pioneers who are leveraging their skills from the scoreboard into thriving careers, businesses, and movements off the field. For more information, visit pick up a copy at your local newsstand today. Contact Information:Kerrie Lee BrownVice President of Publishing and Editor-in-Chief, SUCCESS® About SUCCESS® EnterprisesFounded in 1897, SUCCESS® is a leading multimedia company dedicated to personal and professional development. Through SUCCESS® magazine, newsletters, videos, and more, SUCCESS® inspires individuals to dream big and live their own definition of success. Optimism, determination, and resilience drive SUCCESS'® mission to provide individuals with tools and education for continuous growth and lasting success. For more information, visit A photo accompanying this announcement is available at in to access your portfolio
Yahoo
an hour ago
- Yahoo
Single infusion of CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma
New long-term CARTITUDE-1 data show one-third of patients treated with cilta-cel remain progression-free at five years1 CARTITUDE-4 analysis shows overall survival and progression-free benefits in standard and high-risk subgroups across prior lines of treatment2 BEERSE, BELGIUM, June 03, 2025 (GLOBE NEWSWIRE) -- Janssen-Cilag International NV, a Johnson & Johnson company, today announced new long-term follow-up data from the Phase 1b/2 CARTITUDE-1 study demonstrating 33 percent (n=32) of patients in the study (n=97) with relapsed or refractory multiple myeloma (RRMM) treated with CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) achieved progression-free survival (PFS) of five years or more with a single infusion and no maintenance or subsequent anti-myeloma therapy.1 These data underscore Johnson & Johnson's dedication to advancing transformative therapies that aim to reshape the treatment landscape for patients with multiple myeloma. In a subset of 12 patients who underwent serial evaluations at a single site, all were minimal residual disease (MRD) negative (at least 10–5 threshold) and imaging negative throughout five years of post-treatment follow-up.1 Findings were featured in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #7507). The data were also simultaneously published in The Journal of Clinical Oncology.3 'This new evidence shows how a single infusion of cilta-cel can help patients survive without disease progression much longer than previously thought possible in this setting, and without any maintenance or subsequent treatment,' said Peter M. Vorhees, M.D., Clinical Professor of Hematology and Oncology at Atrium Health, Levine Cancer Institute at Wake Forest University School of Medicine.* 'In a heavily pre-treated population, a third of patients remained treatment- and progression-free for at least five years.' The Phase 1b/2 CARTITUDE-1 study (n=97) evaluated cilta-cel for the treatment of heavily pre-treated patients with RRMM.1 Patients who remained progression-free for at least five years (n=32) had a median of six prior lines of therapy and included subgroups with high-risk cytogenetics (23.3 percent), extramedullary disease (12.5 percent), triple-class refractory disease (90.6 percent), and penta-drug refractory disease (46.9 percent).1 At a median follow-up of 61.3 months, median overall survival (OS) was 60.7 months (95 percent confidence interval [CI], 41.9, not estimable [NE]), highlighting the depth and durability of response with cilta-cel.1 With an additional ~28 months median follow-up, the safety profile in CARTITUDE-1 was consistent with the known safety profile of cilta-cel, with no new safety signals observed.1 There were two newly reported second primary malignancies (both solid tumours), two additional neurologic events, not related to cilta-cel, including one case each of encephalopathy and taste disorder, four new-onset Grade 3 infections (not related to cilta-cel), and no new Parkinsonism events or cranial nerve palsies.1 'The latest results from the CARTITUDE-1 study mark a major milestone in the treatment of relapsed and refractory multiple myeloma, with a single infusion of cilta-cel delivering unprecedented long-term outcomes,' said Ester in't Groen, EMEA Therapeutic Area Head Haematology, Johnson & Johnson Innovative Medicine. 'In a patient population where median overall survival has traditionally been around one year, it is promising to see many people now living beyond five years - a testament to the transformative potential of cilta-cel.' Additional data from another cilta-cel study, CARTITUDE-4, also presented at the 2025 ASCO Annual Meeting, evaluated PFS and OS versus standard of care (SOC) in prespecified subgroups, including patients with standard and high-risk cytogenetics, extramedullary disease, and by line of therapy (Abstract #7539).2 Results demonstrated that cilta-cel improved PFS and OS across subgroups versus SOC. In patients with standard risk-disease after 1 to 3 prior lines of treatment, PFS curves indicate stability in survival rates.2 'Across our multiple myeloma portfolio and pipeline, we are shifting from treating to progression to treating to cure,' said Jordan Schecter, M.D., Vice President, Research & Development, Multiple Myeloma, Johnson & Johnson Innovative Medicine. 'Our focus is to extend patient survival, and based on our expertise of the disease biology, develop treatment regimens with curative potential.' Results will also be presented at the upcoming European Hematology Association (EHA) 2025 Congress. About CARTITUDE-1CARTITUDE-1 (NCT03548207) is a Phase 1b/2, open-label, multicentre study evaluating the efficacy and safety of cilta-cel in adults with relapsed and/or refractory multiple myeloma (RRMM), 99 percent of whom were refractory to the last line of treatment; 88 percent of whom were triple-class refractory, meaning their cancer did not or no longer responds to an immunomodulatory agent (IMiD), a proteasome inhibitor (PI) and an anti-CD38 antibody.4,5 The primary objective of the Phase 1b portion of the study, involving 29 patients, was to characterise the safety and confirm the dose of cilta-cel, informed by the first-in-human study with LCAR-B38M CAR-T cells (LEGEND-2).4 Based on the safety profile observed in this portion of the study, outpatient dosing is being evaluated in additional CARTITUDE studies. The Phase 2 portion of the study is evaluating the efficacy of cilta-cel with overall response as the primary endpoint.4 The study involved patients with heavily pretreated RRMM who historically have an expected median progression-free survival of <6 months and median overall survival of ~1 year.4 About CARTITUDE-4 CARTITUDE-4 (NCT04181827) is the first international, randomised, open-label Phase 3 study evaluating the efficacy and safety of cilta-cel versus pomalidomide, bortezomib and dexamethasone (PVd) or daratumumab, pomalidomide and dexamethasone (DPd) in adult patients with relapsed and lenalidomide-refractory multiple myeloma who received one to three prior lines of therapy, including a PI and an IMiD.6 Patients were randomised to receive either a sequence of apheresis, bridging therapy, lymphodepletion and cilta-cel (n=208) or standard of care (SOC), which included PVd or DPd (n=211).7 The primary outcome measure for the study is progression free survival (PFS), defined as the time from the date of randomisation to the date of first documented disease progression, as defined in the International Myeloma Working Group (IMWG) criteria, or death due to any cause.6 Safety, overall survival (OS), minimal residual disease (MRD) negativity rate and overall response rate are secondary endpoints.6 About Cilta-cel Cilta-cel is a B-cell maturation antigen (BCMA)-directed, genetically modified autologous T-cell immunotherapy that involves reprogramming a patient's own T-cells with a transgene encoding chimeric antigen receptor (CAR) that directs the CAR-positive T-cells to eliminate cells that express BCMA.7 BCMA is primarily expressed on the surface of malignant multiple myeloma B-lineage cells, as well as late-stage B-cells and plasma cells.8 The cilta-cel CAR protein features two BCMA-targeting single domains designed to confer high avidity against human BCMA.7 Upon binding to BCMA-expressing cells, the CAR promotes T-cell activation, expansion, and elimination of target cells.9 In April 2024, the European Commission (EC) approved an indication extension for cilta-cel for the treatment of adults with RRMM who have received at least one prior therapy, including an iMiD and a PI, have demonstrated disease progression on the last therapy, and are refractory to lenalidomide. In April 2024, cilta-cel was approved in the U.S. for the second-line treatment of adult patients with relapsed or refractory myeloma who have received at least one prior line of therapy including a PI, an iMiD, and who are refractory to lenalidomide. In December 2017, Janssen Biotech, Inc., a Johnson & Johnson company, entered into an exclusive worldwide licence and collaboration agreement with Legend Biotech USA, Inc., to develop and commercialise cilta-cel.10 For a full list of adverse events and information on dosage and administration, contraindications and other precautions when using cilta-cel please refer to the Summary of Product Characteristics.7 In line with European Medicines Agency (EMA) regulations for new medicines and those given conditional approval, cilta-cel is subject to additional monitoring.7 About Multiple Myeloma Multiple myeloma is currently an incurable blood cancer that affects a type of white blood cell called plasma cells, which are found in the bone marrow.11,12 In multiple myeloma, these plasma cells continue to proliferate, accumulating in the body and crowding out normal blood cells, often causing bone destruction and other serious complications.13 In the European Union, it is estimated that more than 35,000 people were diagnosed with multiple myeloma in 2022, and more than 22,700 patients died.14 Patients living with multiple myeloma experience relapses which become more frequent with each line of therapy while remissions become progressively shorter.15,16,17 Whilst some people diagnosed with multiple myeloma initially have no symptoms, others can have common signs and symptoms of the disease, which can include bone fracture or pain, low red blood cell counts, fatigue, high calcium levels, infections, or kidney problems.18,19 About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at Follow us at Janssen-Cilag International NV, Janssen Pharmaceutica NV, Janssen-Cilag Limited, Janssen Biotech, Inc., and Janssen Research & Development, LLC are Johnson & Johnson companies. This press release contains 'forward-looking statements' as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of cilta-cel. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialise, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes in behaviour and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned 'Cautionary Note Regarding Forward-Looking Statements' and 'Item 1A. Risk Factors,' and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. * Dr Peter M. Vorhees, M.D., Clinical Professor of Hematology and Oncology at Atrium Health, Levine Cancer Institute at Wake Forest University School of Medicine, has provided consulting, advisory, and speaking services to Janssen-Cilag International NV; he has not been paid for any media work. ### 1 Voorhees, P. Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM). Oral presentation. American Society of Clinical Oncology (ASCO) Annual Meeting; May 30 – June 3, 2025.2 Sidana, S. Ciltacabtagene autoleucel (cilta-cel) vs standard of care (SOC) in patients (pts) with relapsed/refractory multiple myeloma (MM): CARTITUDE-4 survival subgroup analyses. Oral presentation. American Society of Clinical Oncology (ASCO) Annual Meeting; May 30 – June 3, 2025.3 Voorhees, P. Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM). J Clin Oncol. 43, 7507-7505. DOI:10.1200/JCO.2025.43.16_suppl.7507 4 A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma (CARTITUDE-1). Available at: Study Details | A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma | Last accessed: May 2025.5 Lin Y, et al. CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma. Oral presentation. American Society of Clinical Oncology (ASCO) Annual Meeting 2023.6 A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE4). Available at: Last accessed: May 2025.7 European Medicines Agency. CARVYKTI (ciltacabtagene autoleucel) Summary of Product Characteristics. Available at: Last accessed: May 2025.8 Cho, et al. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy. Front Immunol 2018;10(9):1821. 9 Tai, et al. Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy 2015;7(11):1187-1199. 10 Janssen Enters Worldwide Collaboration and License Agreement with Chinese Company Legend Biotech to Develop Investigational CAR-T Anti-Cancer Therapy. Available at: Last accessed: May 2025.11 Abdi, et al. Drug resistance in multiple myeloma: latest findings on molecular mechanisms. Oncotarget 2013;4(12):2186-2207.12 American Society of Clinical Oncology. Multiple myeloma: introduction. Available at: Last accessed: May 2025. 13 City of Hope. Multiple Myeloma: Causes, Symptoms & Treatments. Available at: Last accessed: May 2025. 14 ECIS. European Cancer Information System. Estimates of cancer incidence and mortality in 2022, by country. Multiple myeloma. Available at: Last accessed: May 2025.15 Bhatt P, Kloock C, Comenzo R. Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse. Curr Oncol. 2023;30(2):2322-2347.16 Hernández-Rivas JÁ, et al. The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies. Biomark Res. 2022;10(1):1-23.17 Gavriatopoulou M, et al. Metabolic Disorders in Multiple Myeloma. Int J Mol Sci. 2021;22(21):11430.18 American Cancer Society. What is Multiple Myeloma? Last accessed: May 2025.19 American Cancer Society. Multiple Myeloma Early Detection, Diagnosis, and Staging. Last accessed: May 2025 CONTACT: Media contact: Jenni Mildon jmildon@ +44 7920 418 552 Investor contact: Lauren Johnson investor-relations@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
